Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients

Yuqin Song, Jun Zhu, Qingqing Cai et al.|Journal of Cancer Research and Therapeutics|2024

Cited by 2